CA-CEPTON-TECHNOLOGIES
19.8.2021 15:02:13 CEST | Business Wire | Press release
Leading lidar solutions provider Cepton received two recognitions at Tech.AD Europe this year for its innovations, adding to the company’s growing portfolio of award-winning lidar solutions across industries.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210819005247/en/
Tech.AD is a leading technical conference in Europe focused on technologies for autonomous driving (AD) and the advancements of artificial intelligence (AI) technology in the automotive industry. The annual Tech.AD Europe Award exclusively honors "extraordinary projects in the automotive industry and celebrates exceptional solutions & innovations." Awards are announced after submissions are rated by a jury of some of the top subject matter experts in Europe.
Cepton was recognized in the category of Most Innovative Use of Artificial Intelligence & Machine Learning in the Development of Autonomous Vehicles & Respective Technologies for its Nova lidar . Second place award-winner in this category, Nova is a pathbreaking miniature, wide field of view (FOV) lidar sensor for near-range perception in advanced driver assistance systems (ADAS), autonomous vehicle (AV) and autonomous ground vehicle (AGV) applications. Nova provides an attractive combination of performance, compactness, FOV coverage and affordability and enables a range of use cases such as high-accuracy blind spot detection, small object detection, automated park assist and free space estimation around the vehicle.
Another award was given to a Cepton lidar-enabled smart cities project - Traffic Monitoring as Source of Training Data for Autonomous Vehicles - by Cepton partner ALP.Lab , which won the top prize in the category of Most Advanced Real-Life Testing & Simulation Techniques in Autonomous Driving . Deployed in the City of Graz, the ALP.Lab project utilizes Cepton’s Helius ® Smart Lidar System and Vista® -P lidars to enable advanced, real-time, 3D traffic and pedestrian analytics. According to ALP.Lab, “the enormous amount of time and expense involved in collecting training data for ADAS/AD development can be dramatically reduced by this new and sustainable lidar perception based technique focused on specific roads and environments likely to generate the most diverse and difficult driving environments.”
The Tech.AD Europe awards represent a continuation of past recognitions of Cepton’s lidar innovations. Previously, Cepton received awards for its lidar solutions across multiple applications, including the AUVSI XCELLENCE in Innovation Award in 2019 for the Sora™ lidar, the Security Today New Product of the Year Award in 2019 in the Perimeter Protection category for the first generation of Helius® known as Vista-Edge, the Autonomous Vehicle Technology ACES Award in 2020 jointly with Cepton partner Dataspeed for the Vista® -P lidar, and the CES Innovation Award in 2020 in two categories – Smart Cities and Tech for a Better World – for the Helius® Smart Lidar system, that also includes our Vista® -P lidars.
Dr. Jun Pei, CEO of Cepton, said: “The awards at Tech.AD Europe were not only based on jury selection, but also based on the voting of all of the conference attendees representing leading automotive OEMs, autonomous vehicle companies, Tier 1 suppliers, and other R&D organizations worldwide. We are grateful for this recognition and what it represents for the continued innovation we are bringing to market using our MMT® lidar technology. Increasingly, the role of Cepton lidars in the future of mobility is becoming clear worldwide and we are pleased to work with global partners such as ALP.Lab in advancing safety and autonomy.”
About Cepton Technologies, Inc.
Cepton provides state-of-the-art, intelligent, lidar-based solutions for a range of markets such as automotive (ADAS/AV), smart cities , smart spaces and smart industrial applications. Cepton’s patented MMT® -based lidar technology enables reliable, scalable and cost-effective solutions that deliver long range, high resolution 3D perception for smart applications.
Founded in 2016 and led by industry veterans with over two decades of collective experience across a wide range of advanced lidar and imaging technologies, Cepton is focused on the mass market commercialization of high performance, high quality lidar solutions. Cepton is headquartered in San Jose, California, USA, with a presence in North America, Germany, Japan, India and China, to serve a fast-growing global customer base. For more information, visit www.cepton.com and follow us on Twitter and LinkedIn .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210819005247/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom